Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Ioannis Avgerinos,1 Aris Liakos,1,2 Apostolos Tsapas,1–3 Eleni Bekiari1,2 1Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Diabetes Centre, Second Medical Department, Aristotle University of Thessal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Avgerinos I, Liakos A, Tsapas A, Bekiari E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	dapagliflozin sodium-glucose co-transporter 2 (sglt-2) inhibitors type 2 diabetes cardiovascular risk Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/e39976d9cd7b4b7fbd4e45ff5994375d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e39976d9cd7b4b7fbd4e45ff5994375d
record_format	dspace
spelling	oai:doaj.org-article:e39976d9cd7b4b7fbd4e45ff5994375d2021-12-02T03:15:14ZCardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin1178-7007https://doaj.org/article/e39976d9cd7b4b7fbd4e45ff5994375d2019-12-01T00:00:00Zhttps://www.dovepress.com/cardiovascular-risk-reduction-in-type-2-diabetes-therapeutic-potential-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Ioannis Avgerinos,1 Aris Liakos,1,2 Apostolos Tsapas,1–3 Eleni Bekiari1,2 1Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Diabetes Centre, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Harris Manchester College, University of Oxford, Oxford, UKCorrespondence: Ioannis AvgerinosClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Konstantinoupoleos 49, Thessaloniki 54642, GreeceEmail iavgerik@auth.grAbstract: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are currently used as second-line therapy for treatment of patients with type 2 diabetes mellitus (T2DM). Based on the results from dedicated cardiovascular outcome trials (CVOTs), current guidelines suggest the use of SGLT-2 inhibitors for patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) or heart failure. The cardiovascular safety profile of dapagliflozin, a novel SGLT-2 inhibitor, has been recently explored in large CVOTs. Treatment with dapagliflozin reduced the risk of the composite outcome of cardiovascular mortality or hospitalization for heart failure compared with placebo, both among patients with T2DM who had or were at risk of ASCVD, as well as among patients with heart failure and a reduced ejection fraction. The observed cardiovascular benefit was mainly attributed to the lower rate of hospitalization for heart failure. Additionally, treatment with dapagliflozin was associated with a lower rate of renal adverse events. The safety and efficacy of dapagliflozin on glycemic and non-glycemic endpoints has been also well established in a series of other clinical trials and real-word studies. The aim of the present review is to summarize the available evidence regarding the cardiovascular profile of dapagliflozin in patients with T2DM. Overall, by reducing the rate of hospitalization for heart failure and ameliorating renal adverse events, dapagliflozin is a valuable option for the management of patients with T2DM and multiple cardiovascular risk factors.Keywords: dapagliflozin, sodium-glucose co-transporter 2 inhibitors, SGLT-2 inhibitors, type 2 diabetes, cardiovascular riskAvgerinos ILiakos ATsapas ABekiari EDove Medical Pressarticledapagliflozinsodium-glucose co-transporter 2 (sglt-2) inhibitorstype 2 diabetescardiovascular riskSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 12, Pp 2549-2557 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	dapagliflozin sodium-glucose co-transporter 2 (sglt-2) inhibitors type 2 diabetes cardiovascular risk Specialties of internal medicine RC581-951
spellingShingle	dapagliflozin sodium-glucose co-transporter 2 (sglt-2) inhibitors type 2 diabetes cardiovascular risk Specialties of internal medicine RC581-951 Avgerinos I Liakos A Tsapas A Bekiari E Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
description	Ioannis Avgerinos,1 Aris Liakos,1,2 Apostolos Tsapas,1–3 Eleni Bekiari1,2 1Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Diabetes Centre, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Harris Manchester College, University of Oxford, Oxford, UKCorrespondence: Ioannis AvgerinosClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Konstantinoupoleos 49, Thessaloniki 54642, GreeceEmail iavgerik@auth.grAbstract: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are currently used as second-line therapy for treatment of patients with type 2 diabetes mellitus (T2DM). Based on the results from dedicated cardiovascular outcome trials (CVOTs), current guidelines suggest the use of SGLT-2 inhibitors for patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) or heart failure. The cardiovascular safety profile of dapagliflozin, a novel SGLT-2 inhibitor, has been recently explored in large CVOTs. Treatment with dapagliflozin reduced the risk of the composite outcome of cardiovascular mortality or hospitalization for heart failure compared with placebo, both among patients with T2DM who had or were at risk of ASCVD, as well as among patients with heart failure and a reduced ejection fraction. The observed cardiovascular benefit was mainly attributed to the lower rate of hospitalization for heart failure. Additionally, treatment with dapagliflozin was associated with a lower rate of renal adverse events. The safety and efficacy of dapagliflozin on glycemic and non-glycemic endpoints has been also well established in a series of other clinical trials and real-word studies. The aim of the present review is to summarize the available evidence regarding the cardiovascular profile of dapagliflozin in patients with T2DM. Overall, by reducing the rate of hospitalization for heart failure and ameliorating renal adverse events, dapagliflozin is a valuable option for the management of patients with T2DM and multiple cardiovascular risk factors.Keywords: dapagliflozin, sodium-glucose co-transporter 2 inhibitors, SGLT-2 inhibitors, type 2 diabetes, cardiovascular risk
format	article
author	Avgerinos I Liakos A Tsapas A Bekiari E
author_facet	Avgerinos I Liakos A Tsapas A Bekiari E
author_sort	Avgerinos I
title	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
title_short	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
title_full	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
title_fullStr	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
title_full_unstemmed	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
title_sort	cardiovascular risk reduction in type 2 diabetes: therapeutic potential of dapagliflozin
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/e39976d9cd7b4b7fbd4e45ff5994375d
work_keys_str_mv	AT avgerinosi cardiovascularriskreductionintype2diabetestherapeuticpotentialofdapagliflozin AT liakosa cardiovascularriskreductionintype2diabetestherapeuticpotentialofdapagliflozin AT tsapasa cardiovascularriskreductionintype2diabetestherapeuticpotentialofdapagliflozin AT bekiarie cardiovascularriskreductionintype2diabetestherapeuticpotentialofdapagliflozin
_version_	1718401892097196032

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Ejemplares similares